Jivi® prophylaxis patients who experienced zero bleeds1

Study Design Chart
  • Patients with 0 or 1 spontaneous bleed (defined as a joint or muscle bleed and no identified trauma) during weeks 1-10 of the main study.1
  • Patients with 2 or more spontaneous bleeds (defined as a joint or muscle bleed and no identified trauma) during weeks 1-10 of the main study.1
  • Patients with 0 bleeds during weeks 10-36 of the trial.1